<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report AUGUST 14, 2000
BARR LABORATORIES, INC.
(Exact name of registrant as specified in its charter)
New York 1-9860 22-1927534
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
Two Quaker Road, P.O. Box 2900, Pomona, New York 10970-0519
(Address of principal executive offices) (Zip code)
(914) 362-1100
(Registrant's telephone number, including area code)
1
<PAGE> 2
BARR LABORATORIES, INC.
CURRENT REPORT DATED AUGUST 14, 2000
Item 5. Other Events
See attached Exhibit 99.2, press release announcing that the U.S. Court
of Appeals, Federal Circuit in Washington, D.C, ruled in favor of the
Company's "double patenting" claim against the patents protecting Eli
Lilly's Prozac(R) anti-depressant. The decision strikes down the patent
that would have expired in December 2003.
Item 7. Financial Statements and Exhibits
(c) Exhibit Number Exhibit
99.2 Registrant's August 9, 2000 press release announcing
that the U.S. Court of Appeals, Federal Circuit in
Washington, D.C, ruled in favor of the Company's
"double patenting" claim against the patents
protecting Eli Lilly's Prozac(R) anti-depressant. The
decision strikes down the patent that would have
expired in December 2003.
2
<PAGE> 3
BARR LABORATORIES, INC.
CURRENT REPORT DATED AUGUST 14, 2000
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
BARR LABORATORIES, INC.
Date: August 14, 2000 /S/ William T. McKee
--------------------
William T. McKee
Chief Financial Officer
3
